Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vertex Pharmaceuticals Incorporated (VRTX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance

Vertex Pharmaceuticals IncorporatedTrade
ZIM Integrated Shipping Services LtdTrade

Price performance (Past 24H)

Key statistics

Vertex Pharmaceuticals Incorporated vs ZIM Integrated Shipping Services Ltd — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while ZIM Integrated Shipping Services Ltd trades at $29.21 (market cap $3.63B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 36.9× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

VRTXZIM
Market Cap
$134.06B$3.63B
Sector
HealthIndustrials
52-Week High
$557.96$30.08
52-Week Low
$376.62$12.44
Enterprise Value
$128.18B$7.30B
Dividend Yield
20.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.

The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.

ZIM Integrated Shipping Services Ltd

ZIM Integrated Shipping Services trades at $30.08, up 5.25% with a bullish technical signal from moving averages. The company shows mixed fundamentals with Q2 2026 earnings beating expectations but declining profitability margins year-over-year. Valuation metrics appear attractive with P/S of 0.56 and P/B of 0.93, though analyst sentiment remains divided amid merger uncertainty with Hapag-Lloyd.

The stock faces headwinds from the uncertain $4.2 billion takeover deal and declining net income margins, but strong transpacific positioning and recent earnings beats provide upside potential. Current price sits well above the $18.25 consensus target, suggesting limited near-term upside according to Wall Street analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX

About ZIM Integrated Shipping Services Ltd

ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.

Read more on ZIM